The expression patterns of the two subunits of the metabotropic GABAB receptor, GABABR1 and GABABR2, vary among various neural regions and their relative expression in the rat central vestibular system remains unknown. To identify the expression patterns of these two subunits of the metabotropic GABAB receptor in the vestibular nucleus of adult rats, double immunofluorescence experiments were performed. GABABR1 or GABABR2 immunoreactivity was observed in neurons and neuropilar elements of the vestibular nuclear complex and its subgroups x and y. These neurons were oval, multipolar, fusiform or triangular in shape. In contrast to other brain regions, individual neurons or neuropil within the various vestibular subnuclei and subgroups displayed comparable levels of GABABR1 and GABABR2 immunoreactivity. Double immunofluorescence experiments further demonstrated the coexpression of GABABR1 and GABABR2 receptor subunits in individual central vestibular neurons. The present findings provide histological evidence of the heterodimeric nature of GABAB receptors that mediate inhibitory neurotransmission in the rat vestibular nuclei.

Keywords:
Coexpression, GABAB receptors, Immunohistochemistry, Vestibular nucleus
This content is only available via PDF.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.